Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 56 (-3.4%)ASK Investment₹ 925 (0%)CIAL ₹ 444 (1.4%)CSK ₹ 258 (-2.3%)ESDS Software₹ 468 (4.5%)Garuda Aerospace₹ 468 (-3.5%)India Carbon₹ 895 (0%)Indian Potash₹ 2850 (0%)Inox Clean₹ 725 (0%)Lava ₹ 52 (0%)Matrix Gas₹ 14 (-6.7%)Motilal Oswal₹ 12.5 (-3.5%)MSEI ₹ 6.35 (1.6%)NCDEX ₹ 368 (-4.2%)NSE ₹ 1995 (0.5%)Onix Renewable₹ 56 (-15.2%)OYO ₹ 24 (0%)OYO Assets₹ 9.95 (-17.1%)Pharmeasy ₹ 6.25 (0%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-9.7%)RRP S4E₹ 158 (-6%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)Ticker Ltd₹ 32 (0%)Zepto ₹ 42 (-14.3%)

15 Days Price Change

Curis Lifesciences IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2016 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 19.72 Cr
Profile
Price Range 120  to  128 per share
Profile
Min Investment ₹128
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Our business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic onloan license or contract Manufacturing and own brand marketing basis. Our business is majorly on principle to principlebasis with different marketers. As on the date of this Draft Red Herring Prospectus, we cater to more than 100 corporateclients on loan license and/or contract manufacturing basis along with 2 clients for own brand marketing globally ofRepublic of Yemen and Kenya. Our company has commenced manufacturing facility in year 2017, hence, our companyhas experience of more than 5 years in the current line of business of the company. as on the date of this Draft Red HerringProspectus our manufacturing facility at Curis Lifesciences Limited is installed with capacity to manufacture 138 Croretables / year, 15.75 Crore Capsules / year, 1080 Kilolitre Oral Liquid/ year, 270 Tons external preparation / year and 45Tons sterile ophthalmic ointment / year. Our promoters have a vast experience in the pharmaceutical manufacturingIndustry. Driven by the passion for building an integrated pharmaceutical company, backed by their experience, ourPromoters have been the pillars of our Company's growth and have built a strong value system for our Company. Withtheir enriching experience and progressive thinking, we aim to continue to grow in the pharmaceutical industry Read More

Basic Info

Face Value 10 per share

Price 120  to  128 per share

P/E (x) 12.4

Sales( Cr.) 49

PAT( Cr.) 6

EPS 10.3

Draft Prospectus

Exchange NSE-SME

Promoter

Company Promoters

Dharmesh Dashrathbhai Patel Siddhant Jayantibhai Pawasia Piyush Gordhanbhai Antala Jaimik Mansukhbhai Patel

Pre Issue Share Holding 92.68%

Post Issue Share Holding 68.03%

Listing Details:

Listing Price: 146.1

Listing Gain: 12.39%

Current Price: 127

Gain On Issue: 127 | 0%

GMP: 9

GMP %: 7 %

IPO Tentative Timetable

Opening Date Nov 07, 2025
Closing Date Nov 11, 2025
Allotment Nov 12, 2025
Refund Nov 13, 2025
Delivery of Shares Nov 13, 2025
Listing Date Nov 14, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 2000 256,000
Retail (Max) -- -- --
S-HNI (Min) 1 2000 256,000
S-HNI (Max) 3 6000 768,000
B-HNI (Min) 4 8000 1,024,000

Objective of the Issue

i.Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities ii.Capital Expenditure towards Construction of a Storage Facility iii.Pre-payment/Repayment of outstanding Secured Loans iv.Product Registrations in other countries v.Funding our Working Capital Requirements vi.General Corporate Purpose.

Issue

Category Nos Bid Bid (x)
QIB 0 39335000 0x
NII 0 35671000 0x
Retail 0 31706000 0x
EMP 0 0 0x
Total 0 106712000 0x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Curis Lifesciences Profit & Loss

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 24 35 36 49
Other Income 0 1 0 1
Total Income 24 36 36 50
Total Expenditure 20 32 27 40
Operating Profit 4 4 9 10
Interest 2 1 1 1
Depreciation 1 1 1 1
Exceptional Income / Expenses 0 0 0 0
Profit Before Tax 1 2 7 8
Provision for Tax 1 0 2 2
Profit After Tax 0 2 5 6
Adjustments 0 0 0 0
Profit After Adjustments 0 2 5 6
Adjusted Earnings Per Share 0.9 3.4 8.8 10.3

Curis Lifesciences Balance Sheet

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds -1 1 6 16
Minority's Interest 0 0 0 0
Borrowings 12 10 9 7
Other Non-Current Liabilities 0 0 1 1
Total Current Liabilities 16 19 18 18
Total Liabilities 27 30 34 43
Fixed Assets 12 12 12 11
Other Non-Current Assets 0 0 0 0
Total Current Assets 15 17 22 31
Total Assets 27 30 34 43

Curis Lifesciences Cash Flow

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0
Cash Flow from Operating Activities 5 3 0 -2
Cash Flow from Investing Activities -0 -1 -0 -0
Cash Flow from Financing Activities -5 -3 0 2
Net Cash Inflow / Outflow -0 0 0 -0
Closing Cash & Cash Equivalent 0 0 0 0

Curis Lifesciences Ratios

# Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.9 3.41 8.85 10.29
CEPS(Rs) 2.27 4.73 10.08 11.42
DPS(Rs) 0 0 0 0
Book NAV/Share(Rs) -1.64 1.83 10.68 27.34
Core EBITDA Margin(%) 15.16 9.34 23.74 19.43
EBIT Margin(%) 12.06 10.03 22.71 19.1
Pre Tax Margin(%) 5.17 6.18 20.17 16.83
PAT Margin (%) 2.07 5.29 13.69 12.43
Cash Profit Margin (%) 5.25 7.34 15.6 13.8
ROA(%) 1.8 6.56 15.3 15.98
ROE(%) 0 3669.86 141.51 55.25
ROCE(%) 17.12 20.96 40.22 34.25
Receivable days 95.98 81.29 100.82 65.45
Inventory Days 82.63 53.97 72.22 101.63
Payable days 359.28 228.97 274.17 121.29
PER(x) 0 0 0 0
Price/Book(x) 0 0 0 0
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 0.76 0.47 0.48 0.43
EV/Core EBITDA(x) 4.98 3.86 1.96 2.11
Net Sales Growth(%) 0 49.29 0.3 38.18
EBIT Growth(%) 0 24.14 127.24 16.22
PAT Growth(%) 0 280.85 159.53 25.44
EPS Growth(%) 0 280.83 159.53 16.26
Debt/Equity(x) -19.5 16.1 2.91 0.96
Current Ratio(x) 0.94 0.94 1.21 1.78
Quick Ratio(x) 0.6 0.66 0.72 0.73
Interest Cover(x) 1.75 2.61 8.95 8.41
Total Debt/Mcap(x) 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 36% 27% 0% 0%
Operating Profit CAGR 11% 36% 0% 0%
PAT CAGR 20% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 55% 1289% 967% 967%
ROCE Average 34% 32% 28% 28%

Company Contact Information

Curis Lifesciences Ltd.

Nikhil Purohit

91 99045 22543

cs@curisls.com

P F-23, G I D C Sanand - I I Industrial Estate, Sanand

IPO Lead Manager(s)

Curis Lifesciences Ltd.

Finaax Capital Advisors Pvt Ltd

Registrar Info

Curis Lifesciences Ltd.

MUFG Intime India Pvt Ltd.

C 101, 247 Park, LBS Marg, Vikhroli (W), Mumbai (Old Address:) C-13 Pannalal Silk Compound, L B S Marg, Bhandup Mumbai Maharashtra

+91 810 811 8484

91-022-49186060

rnt.helpdesk@in.mpms.mufg.com

https://in.mpms.mufg.com/

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!